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PERBANGAN PENGESPRESAN PROTEIN ANTARA KANSER PAYUDARA 
DENGAN KANSER KOLOREKTAL 
 
Abstrak 
 
  Sehingga hari ini, kanser kekal sebagai masalah kesihatan yang utama 
secara global. Kanser payudara merupakan kanser yang paling biasa dalam kalangan 
wanita manakala kanser kolorektal ialah kanser yang ketiga umum untuk kedua-dua 
jantina di seluruh dunia. Memandangkan kanser payudara dan kanser kolorektal 
adalah antara kanser yang paling umum di Malaysia, kami ingin mengenalpasti 
penanda bio yang boleh digunakan untuk tujuan diagnosis dan rawatan bagi 
kedua-dua jenis kanser ini. Keinginan ini dicapai melalui perbandingan 
pengekspresan protein antara tisu-tisu kanser payudara dan kanser kolorektal dengan 
tisu-tisu normalnya. Dua puluh lima pasang tisu-tisu kanser payudara dan kolorektal 
serta tisu normal dikutip dari Hospital Umum Pulau Pinang (GH) selepas 
memperolehi keizinan daripada pesakit atau saudara terdekat pesakit. Protein-protein 
diekstrak daripada tisu-tisu dengan keadah pengekstrakan bersambungan yang 
mengandungi dua jenis penyangga, iaitu penyangga TRIS dan penyangga TLB. 
Protein-protein tersebut dipisahkan oleh elektroforesi dwi-dimensi. Dengan 
menggunakan perisian analisis gambar gel, proteome bagi tisu-tisu daripada 
kedua-dua jenis kanser dibandingkan antara: i) tisu kanser payudara dengan tisu 
normal; ii) tisu kanser kolorektal dengan tisu normal dan iii) kanser payudara dengan 
XXIV 
 
kanser kolorektal. Tompok-tompok protein yang diekpresi pada kadar yang berbeza 
dikeluarkan daripada gel untuk analisis pengenalpastian protein selanjutnya oleh 
LC-MS/MS. Bagi kanser payudara, tropomyosin isoform dikenalpasti sebagai 
protein kawalan meningkat pada semua peringkat N bagi semua bangsa. 
Calrecticulin (TLB), PDI A3 (TLB), Hsp 70 (TLB), Hsp 60 dan PDI dikenalpasti 
sebagai protein kawalan meningkat pada peringkat N0 dan N1 bagi semua bangsa, 
kecuali peringkat N2. Ujian statistik PCA dan LDA menunjukkan bahawa 
penggunaan PDI A3 (TRIS), ‘activation-induced cytidine deaminase’, 
‘alpha-1-antitrypsin precursor’, ‘alpha-1-antitrypsin, chain A’, ‘haptoglobin’, PDI, 
PDI A3 (TLB), ‘annexin A3’, ‘annexin V’, ‘heat shock protein 70 kDA 1A’, 
‘calrecticulin’ dan ‘tubulin alpha chain’ dapat digunakan dengan pasti untuk 
menunjukkan keadaan patologi kanser payudara. Bagi kanser kolorektal, annexin A3 
dikenalpasti sebagai protein kawalan meningkat pada semua peringkat N (iaitu N0, 
N1 dan N2) serta bangsa yang dikaji. Ujian statistik PCA dan LDA menunjukkan 
bahawa ‘alpha-1-antitrypsin precursor’, ‘alpha-1-antitrypsin, chain A’, PDI A3 
(TRIS), HSP 90 (TRIS), ‘tubulin, beta polypeptide’ (TRIS), ‘tubulin alpha chain’, 
PDI A3, ‘tubulin, beta polypeptide’ (TLB), ‘ATP synthase’, HSP 70 (TLB), ‘annexin 
A3’, dan ‘tropomyosin alpha-3 chain’ boleh digunakan secara kolektif untuk 
membezakan tisu-tisu dalam keadaan normal atau kanser untuk kanser kolorektal. 
Pada masa yang sama, ‘tubulin, beta polypeptide’ (TLB) dan PDI A3 (TRIS) 
dikenalpasti sebagai protein kawalan bagi kedua-dua jenis kanser. Ujian ‘Western 
blot’ terhadap calrecticulin dan PDI A3 dijalankan untuk mengesahkan keputusan 
XXV 
 
daripada analisis LC-MS/MS dan mesin pencarian MASCOT database. Penyelidikan 
yang selanjutya terhadap calon protein sebagai penanda bio dengan menggunakan 
bilangan sampel yang lebih besar adalah wajar sebelum meneruskan pengembangan 
diagnosis dan rawatan kanser yang selanjutnya. 
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COMPARISON OF PROTEIN EXPRESSION BETWEEN BREAST AND 
COLORECTAL CANCERS 
 
Abstract 
 
  Up to date, cancer remains a major health problem across the globe. Breast 
cancer is the most common cancer among women while colorectal cancer is the third 
most common cancer in both genders worldwide. In view of breast and colorectal 
cancer being among the most common types of cancer in Malaysia, we aimed to 
identify common biomarkers that can be used in the diagnosis or treatment of the 
cancers. This aim is accomplished by studying the protein expression profiles of 
breast and colorectal cancers tissues in comparison with their respective normal 
tissues. Twenty-five pairs of normal and cancerous tissues, respectively for breast 
and colorectal cancer were collected from Penang General Hospital (GH) with 
written informed consent obtained from the patients or their close relatives. Proteins 
were extracted from tissues by using sequential extraction method comprised of two 
extraction buffers, namely TRIS buffer and TLB buffer. The proteins were separated 
by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE). By using the 
image analysis software, the proteome of each tissues type was compared between: i) 
breast cancerous and normal tissues; ii) colorectal cancerous and normal tissues and 
iii) breast and colorectal cancerous tissues. The differentially expressed protein spots 
were excised and subjected to LC-MS/MS analysis. In breast cancer, tropomyosin 
XXVII 
 
isoform was up-regulated in all studied N stages of all ethnics. Calrecticulin (TLB), 
PDI A3 (TLB), Hsp 70 (TLB), Hsp 60 and PDI were detected up-regulated in N0 and 
N1 stage in all the ethnic groups, but not in N2 stage. PCA and LDA statistic test 
revealed that the collectively used of PDI A3 (TRIS), activation-induced cytidine 
deaminase, alpha-1-antitrypsin precursor, alpha-1-antitrypsin, chain A, haptoglobin 
PDI, PDI A3 (TLB), annexin A3, annexin V, heat shock 70 kDa protein 1A, 
calrecticulin and tubulin alpha chain can reliably indicate pathological state of breast 
cancer. In colorectal cancer, annexin A3 was found consistently up-regulated in the 
entire N stages studied (namely N0, N1 and N2) and all ethnics. The PCA and LDA 
statistic test revealed that alpha-1-antitrypsin precursor, alpha-1-antitrypsin, chain A, 
PDI A3 (TRIS), Hsp 90 (TRIS), tubulin, beta polypeptide (TRIS), tubulin alpha 
chain A, PDI A3, tubulin, beta polypeptide (TLB), ATP synthase, Hsp 70 (TLB), 
annexin A3, and tropomyosin alpha 3 chain can be collectively used to differentiate 
normal and cancerous state of colorectal cancer. At the same time, tubulin, beta 
polypeptide (TLB) and PDI A3 (TRIS) were detected up-regulated in both cancer 
types. Western blot on calrecticulin and PDI A3 was carried to validate the result of 
LC-MS/MS analysis and MASCOT database search engine. The usefulness of this 
particular protein as biomarker for colorectal and breast tissues is worth to be further 
evaluated by using a larger sample set before proceeded to subsequent cancer 
diagnosis and treatment intervention. 
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CHAPTER 1  
INTRODUCTION 
 
1.1  Cancer 
1.1.1 Definition of cancer 
  Cancer is a class of clonal malignant disease characterized by uncontrolled 
cell growth, cell invasion and sometimes cell metastasis in body via lymph or blood. 
It is caused by abnormalities in genetic materials involved in cell proliferation, 
differentiation and cell death regulation. The genetic materials involved include 
oncogene, tumor suppressor gene, suicide gene and DNA-repair gene. Mutation or 
damage to these genes make the cell loss or have less ability to correct DNA damage 
and undergo programmatic cell death, resulting in mass of transformed cells to form 
cancer (Hejmadi, 2010, Petrova and Toncheva, 2008). 
 
1.1.2 Carcinogenesis 
  Carcinogenesis is a multistage development of normal cells turning into 
cancer cells which include tumor initiation, promotion and progression (Vincent and 
Gatenby, 2008, Petrova and Toncheva, 2008). The tumor initiation is a malignant 
transformation of normal cells after exposure to carcinogen, such as chemical, 
radiation or virus. Carcinogen distorts cells by inducing DNA mutation, gene 
rearrangement or gene amplification to produce a genotypically altered cell. This 
initiation step is irreversible, permanent and heritable in the transformed cells 
2 
 
(Ruddon, 1994, Vincent and Gatenby, 2008). Tumor promotion is the stage that 
involves cell proliferation and clonal expansion of transformed cells upon 
stimulation of mitotic stimuli such as chronic inflammation. The stimulus is 
non-mutagenic, it caused cell proliferation enhancement and finally produces 
localized tumor that is non-malignant and with self limited growth properties. The 
gradual genetic change is occurred in this preneoplastic lesion (Ruddon, 1994, 
Vincent and Gatenby, 2008). On the contrary, tumor progression refers to formation 
of limitless or invasive growth of tumor. At this stage, the tumor is characterised by 
its karyotypic instability, aneuploidy, and chromosomal abnormalities (Ruddon, 
1994). Figure 1.1 showed the development of a single normal cell to malignant tumor 
(Funes, 2002).  
 
 
Figure 1.1 Development of cancer cells (Funes, 2002) 
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1.2   Breast cancer 
1.2.1 Breast 
  Breasts are located in front of chest wall where extend from clavicle to the 
middle of sternum and continue into the axilla till sixth rib. The breasts are supported 
and hold in place by Cooper’s ligaments. It is composed of fat that covered 
mammary glands that consisted of 15-20 glandular lobes. Each lobe possesses single 
lactiferous duct that further enlarge to form a small and spindle-shaped lactiferous 
sinus. The duct subdivides into smaller duct connect to a gland lobule. There is raised 
nipple surrounded by circular and pigmented areola at the external part of breast 
(Seeley et al., 2006).  
 
  Axillary lymph nodes are classified into three levels according to their 
location relative to pectoralis minor muscle, which laid deep unto the pectoralis 
major muscle; level I lymph nodes are lateral to the border of muscle, level II is 
beneath to the muscle and level III is medial to the edge of the muscle. The 
intramammary nodes are located along the lateral edge of axillary tail and breast. The 
axillary, internal mammary, and intercostals veins are found parallel to the lymphatic 
pathway. Figure 1.2 showed the anatomy of female breast (Pass, 2008). 
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Figure 1.2 Anatomy of female breast (Pass, 2008) 
 
1.2.2 Definition of breast cancer 
  Breast cancer is the cancer originated from breast tissues. It usually forms in 
lactiferous ducts or lobules that supply milk. There are several types of breast cancer 
that are categorized by their origin: ductal carcinoma in situ (DCIS), infiltrating 
ductal carcinoma (IDC), medullary carcinoma and infiltrating lobular carcinoma. 
Among these, infiltrating ductal carcinoma is the most common and aggressive form 
of breast cancer. It is originated and developed in the lactiferous duct, break through 
the duct tube and invade or infiltrate to surrounding tissue of breast. It is one of the 
invasive breast cancer where it can spread to other parts of the body through lymph 
and blood system (Kabbage et al., 2008).  
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1.2.3 Incidence of breast cancer 
  Breast cancer is the most common type of cancer among women in 
Malaysia (Hisham and Yip, 2003) and worldwide (Agarwal et al., 2007). The 
incidence was reported to be the lowest in Asia and Africa, intermediate in 
Mediterrance countries and South America, and the highest in North Europe and 
North America. In year 2000, about 3825 new cases and 1707 death due to breast 
cancer were reported in Malaysia. On the contrary, about 1,050,346 new cases were 
reported and 372,969 death occurred worldwide (Hisham and Yip, 2003). In 
Peninsular Malaysia, the incidence was highest among Chinese, followed by the 
Indian and Malay (Omar, 2006). The risk for breast cancer is increased with age, 
especially those women who used estrogen and progestin MHT after postmenopausal, 
overweight or obese after 18 years old, long menstrual history, physical inactivity, 
personal or family history of breast cancer, and inherited genetic mutation (Society, 
2010) 
 
1.2.4 Tumor, node, metastasis (TNM) staging of breast cancer 
  TNM staging system is one of the commonly used cancer staging systems. It 
is maintained by American Joint Committee on Cancer (AJCC) and International 
Union against Cancer (UICC). TNM staging is determined according to the result of 
physical examination, biopsy, and imaging tests. It is based on the size or extent of 
tumor (T), the extent of spreading to lymph nodes (N) and the presence of metastasis 
(M). It is useful to guide doctor in treatment option and prognosis (Society, 2010). 
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The classification of stage grouping and TNM staging system is showed in Table 1.1. 
The description of T, N and M of fifth edition TNM staging system is showed in 
Table 1.2. 
 
Table 1.1 Classification of stage grouping and TNM staging system in breast cancer 
 
AJCC Stage TNM stage 
0 Tis, N0, M0 
IA T1, N0, M0 
IIA T0 -1, N1,M0 
T2, N0, M0 
IIB T2, N1, M0 
T3, N0, M0 
IIIA T0 -2, N2, M0 
T3, N1 -2, M0 
IIIB T4, N0-2, M0 
Any T, N3, M0 
IV Any T, any N, M1 
 
Table 1.2 Description of T, N and M of TNM staging system in breast cancer 
 
Components Description 
T Tis Cancer cells within duct/lobules/not found 
T1 Tumor size ≤ 2cm 
T2 Tumor size ≥ 2cm and ≤ 5cm 
T3 Tumor size ≥ 5cm 
T4 Tumor grown into chest wall/skin 
N N0 No spread to lymph nodes 
N1 Spread to 1 to 9 axillary nodes 
N2 Spread to internal mammary nodes 
N3 Spread to 4 or more axillary lymph nodes, tiny amounts 
found in internal mammary lymph nodes 
M Mx No description. Incomplete information 
M0 No spread to distant site 
M1 Spread to distant site 
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1.3  Colorectal cancer 
1.3.1 Colon, rectum and appendix 
  Colon, rectum and appendix are parts of large intestine in digestive tract 
system. In digestive system, the water and mineral nutrients are absorbed from food 
in colon whereas the waste is then passed through rectum and expelled from anus.  
 
  Colon, a muscular tube about 5 feet long in large intestine, is located either 
in the abdominal cavity or behind the abdominal cavity in the retroperitoneum. It 
consists of four sections: ascending colon, transverse colon, descending colon and 
sigmoid colon (Society, 2008, Seeley et al., 2006). The inner surface is aligned from 
serosa, muscularis, submucosa to mucosa with numerous straight tubular glands 
called crypts. The lymphatic nodule is located within a loose connective tissue called 
lamina propria in mucosa. The blood vessels and nerve is found between connective 
tissue layer and peritoneum in serosa. The rectum is the ~12 cm straight muscular 
tube begins at the end part of sigmoid colon and extended until anal canal. Appendix 
is a ~9 cm small blind tube attached to the caecum (Seeley et al., 2006). Figure 1.3 
showed the anatomy of colon, rectum and appendix (Seeley et al., 2006). 
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Figure 1.3 Anatomy of colon, rectum and appendix (Seeley et al., 2006) 
 
1.3.2 Definition of colorectal cancer 
 Colorectal cancer is cancer that grows in the colon, rectum or appendix. It is 
also called colon cancer or large bowel cancer. There are many forms of colorectal 
cancer which include adenocarcinoma, leimysarcoma, melanoma and neuroendocrine 
tumors. Adenocarcinoma is the most common type of colorectal cancer and 
represents 70% of all malignant disease developed in gastrointestinal tract system 
(Society, 2008, Kumar et al., 1997). It refers to tumor originates from epithelial 
cell with gland pattern or derived from glandular tissue but not necessarily with 
gland pattern (Kumar et al., 1997).  
 
 
 
 
9 
 
1.3.3 Incidence of colorectal cancer 
  In year 2006, 2866 colorectal cancer cases were registered with National 
Cancer Registry (NCR) and represent 13.2% of all cancer cases registered (Omar, 
2006). The second report of NCR noted that colon cancer is ranked as the third most 
frequent cancer with rectal cancer being ranked as the fifth most common cancer for 
both genders in Malaysia (Balraj and Ruhana, 2007). The occurrence and mortality 
rate of colorectal cancer were higher in men than women (Society, 2008). In 
Peninsular Malaysia, the incidence was the highest among Chinese and the lower in 
Indian and Malay (Omar, 2006). The risk is increased with age (Balraj and Ruhana, 
2007). Besides, personal or family history of colorectal cancer, familial adenomatous 
polyposis, chronic ulceration colitis, obese, diabetes and physical inactivity are also 
the risk factors for development of this malignant disease (Ruddon, 1994).  
 
1.3.4 Tumor, node, metastasis (TNM) staging of colorectal cancer 
  TNM staging system is the most commonly used staging system 
standardized by American Joint Committee on Cancer (AJCC) and International 
Union against Cancer (UICC) for colorectal cancer. The T in TNM staging for 
colorectal cancer is different from breast cancer where it describes how far the 
primary tumor has grown into the intestine wall and nearby areas instead of tumor 
size in breast cancer (Society, 2010). The classification of stage grouping and TNM 
staging system for colorectal cancer is shown in Table 1.3. The description of T, N 
and M of fifth edition TNM staging system is shown in Table 1.4. 
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Table 1.3 Classification of stage grouping and TNM staging system in colorectal 
cancer 
 
AJCC Stage TNM stage 
0 Tis, N0, M0 
I T1-2, N0, M0 
IIA T3, N0, M0 
IIB T4, N0, M0 
IIIA T1-2, N1, M0 
IIIB T3-4, N1, M0 
IIIC Any T, N2, M0 
IV Any T, any N, M1 
 
Table 1.4 Description of T, N, and M of TNM staging system in colorectal cancer 
 
Components Description 
T Tis Grown on mucosa 
T1 Grown through mucosa, submucosa and extends to 
muscularis 
T2 Grown through submucosa and extends to muscularis  
T3 Grown through muscularis and outermost layers of 
colon/rectum but not through it. 
T4a Grown through serosa 
T4b Grown through wall of colon/rectum, attach or invades into 
nearby tissues or organs 
N N0 No spread to lymph nodes 
N1a Spread to 1 nearby lymph node 
N1b Spread to 2-3 nearby lymph nodes 
N1c Small deposits of cancer cells at adipose tissue near lymph 
nodes, but not lymph node. 
N2a Spread to 4-6 nearby lymph nodes 
N2b Spread to 7 or more nearby lymph nodes 
M Mx No description, incomplete information 
M0 No spread to distant site 
M1a Spread to 1 distand organ or set of distant lymph nodes 
M1b Spread to more than 1 distant organ or set of distant lymph 
nodes/distant parts of peritonuem 
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1.4   Comparison between breast and colorectal cancer 
  Extensive works on biomarkers for cancer have been carried out by other 
researchers for many years. Nevertheless, this study is still worth to be carried out. 
The geographical variation in cancer incidence predominantly reflected the 
environmental influences on carcinogenesis, which include dietary, social and culture 
environment factor. This fact indicating that there is a need to identify the most 
beneficial biomarkers specific for Malaysian, making the treatment decision with 
more predictive evidence and diagnosis, and hence reduce the mortality due to cancer 
in Malaysia.  
 
  Currently, most cancer proteomic studies are restricted to individual cancer 
type. In general, this caused the biomarkers to be less useful for cancer staging, 
monitoring and treatment, where the identified biomarkers might not be related to the 
specific organ where tumor spread, growth and metastasis. In this study, we compare 
the proteins expression pattern between breast and colorectal cancer. Both are among 
the most common cancers in Malaysia (Hisham and Yip, 2003, Omar, 2006). There 
are differences in anatomic site, structure, cancer progression and histopathology 
type of tumor between both cancers. Breast cancer is classified based on 
Bloom-Richardson grading system (Grades) and TNM staging system(Bloom and 
Richardson, 1957, Cancer, 1997). Meanwhile, colorectal cancer is classified 
according to Dukes and TNM staging system (Dukes, 1980, Cancer, 1997). In order 
to compare both cancers, a common cancer classification system is employed. The 
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TNM staging system is chosen instead of Grades or Dukes classification. 
Unfortunately, the TNM staging system for breast cancer and colorectal cancer has 
certain classification difference. In general, T describes the tumor size while N the 
region of lymph nodes involved. Precisely, T refers to the size of tumor in breast 
cancer and the level of invasion into nearby structures in colorectal cancer; N denotes 
the lymph nodes location involved in breast cancer and the number of lymph nodes 
involved in colorectal cancer (Cancer, 1997).  
 
  Hence, the first stage of comparison was conducted regardless of the cancer 
stages. Secondly, the comparison was performed between the N0 and N1 stages for 
both cancers. This is because the N0 and N1 classification for both the cancer types 
are the same. Therefore, allowing a common ground to understand the protein 
expression changes within the stages. The study of protein expression pattern among 
ethnicity of patients was also included.  
 
1.5  Cancer proteomic 
1.5.1 Proteomic 
  Proteomic is a study of all proteins encoded by genome in a cell or tissue, 
which include structure and function of the proteins (Dwek and Rawlings, 2002, 
Karp and Lilley, 2007). It is the science that study disease biology with qualitative 
and quantitative comparison of proteomes under two or several different conditions 
(normal versus cancer)(Carpenter and Melath, 2003). In comparison to genomics, 
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proteomics have several advantages in that proteins are more reflective of the 
existing condition of the cell’s microenvironment, where the levels of gene activity 
do not exactly correlate to the corresponding protein expression levels (DaoHai et al., 
2006, Kennedy, 2001, Laronga and Drake, 2007). The proteins can also picture a vast 
cadre of posttranslational modifications which affecting the protein stability, 
localization, interaction and function (Laronga and Drake, 2007). An organism is 
largely governed through the function of proteins rather than deciphered by gene 
alone. Thus, in combination with genomics, proteomics can provide a holistic 
understanding of the biology of cells, organisms, disease processes and response to 
treatment (Kennedy, 2001, Srivastava, 2005).  
 
1.5.2  Protein structure and function 
 Proteins are polymer that made up of 20 or more different amino acids 
linked by peptide bond. The sequence of amino acids is determined by sequence of 
nucleotide encoded in genetic code. Amino acids are molecules consisted of amine 
group, carboxylic group and side chain that vary between amino acids. The key 
elements of the amino acid are carbon, hydrogen, oxygen, and nitrogen. A short 
polymer that made up of less than 20 amino acids is termed peptide instead of protein. 
Peptide bond is also known as amide bond, where a chemical bond formed between 
carboxylic acid and an amino group with the expulsion of water molecule (Petsko 
and Ringe, 2004).  
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 There are four levels of protein structure. The primary structure is referred 
to the amino acid sequence in linear form. The secondary structure is the repeating 
amino acid sequences in either alpha helix, beta sheet or turns form. The tertiary 
structure is the overall shape of a single protein molecule, and finally, several protein 
molecules fold to form quaternary structure. There are mainly three group of protein 
characterized according to their function, which include globular protein (enzyme), 
fibrous protein (structural), and membrane protein (receptor) (Petsko and Ringe, 
2004). 
 
1.5.3 Biomarker 
  Cancer biomarkers discovery is one of the major interests in cancer study. 
Biomarkers are substances that function as indicator in a biological process. It can be 
genes, proteins, small molecules or metabolites (Hale et al., 2003, Issaq and Blonder, 
2009). During the transformation of normal cell into a cancer cell, changes occur at 
protein level due to distorted expression, differential protein modification, changes in 
metabolite activity, and aberrant localization. Proteome analysis yields information 
of these changes and facilitates finding of biomarkers (Issaq and Blonder, 2009, 
Somiari et al., 2005). More specifically, these cancer biomarkers refer to proteins 
that indicate changes in expression due to the abnormal condition or progression of 
cancer (Issaq and Blonder, 2009).  
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  The biomarkers are critical for early detection, diagnosis, treatment, 
monitoring, and prognosis of disease (Srinivas et al., 2002). A biomarker that can 
accurately detect the onset of disease can facilitate diagnosis, permit choice of 
therapy in its pre-invasive stage and consequently reduces the suffering and cost 
associated with the disease (David and Evelyn, 2011, Alfonso et al., 2005). The 
effectiveness and progress of treatment can be monitored with it capability to 
indicate the abnormal condition or progression of cancer. It also can be a potential 
therapeutic target for chemotherapy (Dwek and Rawlings, 2002). Furthermore, 
biomarkers aid drug development, as it indicates the effect of drug during treatment 
of disease (Hale et al., 2003).  
 
  The drawback of early detection of cancer using protein biomarker is the 
reliability of the expression of the biomarker itself. There were instances where 
false-positive results that were due to differential carcinogenesis development pattern 
among population subgroups, and thus resulting in over diagnosis or overtreatment 
on patients. Hence, the study on protein expression pattern within N stages and 
ethnics was carried out in order to identify potential biomarkers that more specific 
for each cancer stages and ethnic of the patients, consequently facilitate and 
optimized personal care on each patient. 
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1.5.4 Proteome analysis of cancer and adjacent normal tissue 
 The most common and effective approach for biomarkers discovery is the 
differential analysis of protein profiles between cancer and adjacent normal tissues 
(Bai et al., 2010, Kim et al., 2009, Luo et al., 2005, Wulfkuhle et al., 2002, Somiari 
et al., 2005). Cell lines are common samples used in cancer proteomics due to its 
known genetic background and consistent cellular composition. However, the growth 
and development of the cancer cells is not only depending on their malignant 
potential. There are interactions within cells, among cells and between cells and 
agents in the microenvironment (Deng et al., 2006). In order to obtain better 
information of protein expression, tissues specimens were used instead of cell lines 
in this study. By comparing the normal and cancerous tissues, the changes of proteins 
expression related to cancer cells development can be recognized (Kennedy, 2001).  
 
1.5.5 Proteomic Research in Cancer 
  Numerous studies have been performed by researchers on different types of 
cancer using proteomic approach. The 2D-PAGE coupled with mass spectrometry, 
isotope coded affinity tags (ICAT), multidimensional protein identification 
technology (MudPIT), protein array technology and surface enhanced 
laser-desorption ionization-time of flight (SELDI-TOF) are among the common 
technologies applied in proteomic study (Dwek and Rawlings, 2002, Somiari et al., 
2005, Srivastava, 2005).  
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  The proteomic analysis of breast normal and cancerous tissue (DCIS) was 
first reported by Wulfuhle et al., (2002). They identified 57 differentially expressed 
proteins between normal and DCIS, these proteins included VDAC, transgelin, Hsp 
27(45), GRP78 (46), and cathepsin. In year 2005, Somiari et al., reported that 
annexin V and HSP 90 were differentially expressed in DCIS, whereas carbonic 
dehyrase, protein disulfide isomerase, gelsolin and fibrinogen beta chain were 
differentially expressed in IDC. Meanwhile, Luo et al., (2005) discovered 10 
up-regulated proteins which included manganese SOD, biliverdin reductase B, 
carbonic anhydrase I and annexin I in IDC. In addition, they also reported 
down-regulated proteins which included fatty acid binding protein 4, cofilin 1, 
profiling 1 and uracil DNA glycosylase in the same type of cancer. They proposed 
the potential used of these markers for diagnostic and also to determine the 
effectiveness of therapy against cancer. Deng et al., (2006) reported that 
alpha-1-antitrypsin, EF-1-beta, cathepsin D, TCTP, SMT3A, and PSMA1 as 
candidate biomarkers for patients with breast cancer.  
 
  In year 2006, Roth et al., (2006) reported a number of differential 
expression proteins between normal and colorectal cancerous tissue, comprised of 18 
up-regulated proteins and 13 down-regulated proteins. Among the up-regulated 
proteins were NADH-ubiquinone oxireductase B18, β-subunit of F0F1-ATPase, liver 
fatty acid-binding protein, soluble carrier family 5 Na
+
-glucose cotransporter 
member 1, insulin-like peptide 5 and gluthathione transferase M4. Among the 
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down-regulated proteins reported were mitochondrial transcription factor 1, lactate 
dehydrogenase, p28 BAB31, glucosamine-6-sulfatasse, caspase-9(Roth et al., 2006). 
Kim et al., (2009) reported 3 novel WD-repeat-motif-bearing proteins that involved 
in actin remodeling, which included Arp2/3 complex subunit 2(p34-Arc), coronin-1A 
and WD-repeat protein 1(Wdr1). These proteins shown significant differ expression 
between normal and cancerous tissue when analyzed using Western blotting 
approach. Another study that evaluated the potential biomarkers or targets for novel 
therapeutic intervention of colorectal cancer was conducted by Dao Hai et al., (2006). 
Their study showed that the oncoprotein hnRNP A1 was highly expressed (80%) in 
cytoplasm of tumors. It could be used as a potential biomarker for treatment. 
Followed by the proteome analysis of adenocarcinoma and adjacent normal tissue, 
TAF9 RNA polymerase II (TAF9) and cytokine inducible SH-2 containing protein 
(CISH) were discovered as biomarker in colorectal cancer (Krasnov et al., 2009). In 
year 2010, Bai et al. reported that carbonic anhydrase II and protein disulfide 
isomerase were down-regulated in colorectal cancer. On the other hand, 
APC-stimulated guanince protein 2B, glutathione S-transferase A3, Arginase and 
zinc finger protein 64 homolog were up-regulated in the same type of cancer. 
 
1.6  Proteomic approach 
1.6.1 Protein extraction 
  Sequential extraction method is an extraction method comprised of two 
extraction buffers to extract proteins in sequential order. The first buffer, namely Tris 
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buffer (TRIS), is used to extract highly soluble (hydrophilic) cytoplasmic proteins 
whereas the poorly soluble (hydrophobic) membrane-associated proteins are 
extracted using thiourea lysis buffer (TLB), the second extraction buffer in sequential 
extraction method. The TLB contains more potent chaotropes and detergents (Molloy 
et al., 1998) when compared with TRIS. Sequential extraction method limits the 
number of protein extracted in each fraction. Therefore, it allows better separation 
and visualization of proteins in gel (Cordwell, 2008).  
 
1.6.2 Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) 
  The 2D-PAGE is the most widespread tool for proteomic study due to its 
ability to map proteome and detect protein expression and post-translational 
modifications (Weiss and Görg, 2009). In first dimension separation, the proteins 
with difference isoelectric point (pI) are rehydrated into an immobilized pH gradient 
(IPG) strip and separated by isoelectric focusing (IEF). The pI is pH at which a 
protein carried net (zero) electrical charges in an electric field (Carpenter et al., 
2004). It is based on the principle that when a protein is placed in a medium with pH 
gradient and applied with electric forces, it moves toward the electrode with opposite 
charge. The proteins either pick up or lose protons until reach their pI and stop 
migrating (Garfin, 2001, Angelika et al., 2000). In second dimension separation, the 
proteins are separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, 
according to molecular weight (Mw) (Weiss and Görg, 2009). The percentage of 
resolving gel used is 10% in order to resolve protein mass range from 30-150 kDa. 
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The proteins on gel are visualized as protein spots by Bio-SafeTM Colloidal 
Coomasie Blue G-250 stain (Garfin, 2001).  
 
1.6.3 In-gel digestion 
  The protein spots of interest are excised from the gel and subjected to in-gel 
digestion. In-gel digestion is a sample preparation step for tandem mass 
spectrometric identification of protein identity after gel electrophoresis (Gam and 
Aishah, 2005, Rosenfeld et al., 1992). It involves four steps which include desalting 
and destaining of gel, reduction and alkylation of cysteines in protein, proteolytic 
cleavage of protein using TPCK-treated trypsin and passive elution of the generated 
peptides from gel pieces. The eluted peptides are then analyzed by mass 
spectrometry (Resing and Ahn, 2004). Subsequently, the characteristic information of 
protein can be obtained. This method was first introduced by Rosenfeld et al., 
(1992). 
 
1.6.4  Reverse phase high performance liquid chromatography tandem mass 
 spectrometry (LC-MS/MS) 
  Reverse-phase (RP) mode HPLC is the most common approach for the 
separation of biological compounds. In HPLC analysis, the sample is applied onto a 
column filled with stationary phase. Then, the components in sample are partitioned 
onto the sorbent material and separated by stream of liquid mobile phase. For 
RV-HPLC, the stationary phase is made up of nonpolar matrix and mobile phase is 
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polar solvent (Dass, 2001). Tandem mass spectrometry is a branching application of 
MS, which capable of selecting an ion formed from a molecules or mixture of 
molecule through collision-induced dissociation and subsequently generate 
characteristic secondary fragment ions (Futrell, 2000). The peptide MW and partial 
sequences of amino acid obtained from MS data can be utilized in search of protein 
Swiss-Prot and NCBRnr database through Mascot Protein Database (MSDB) search 
engine (www.matrixscience.com) and Expasy proteomic server (expasy.org) for 
protein identification (Pyrek, 1997).  
 
1.6.5 Western blot 
  The identity of protein identified by mass spectrometry analysis can be 
verified by Western blotting experiment. It is an immunoblot technique for detection 
of specific proteins in biological sample (Heidebrecht et al., 2009). It involved 
electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels 
to a nitrocellulose membrane, incubation with primary antibody specific to targeted 
proteins, and followed by enzyme linked secondary antibodies against primary 
antibody. When exposed to the substrate, colorimetric reaction occurred and the 
interaction between protein and specific antibody is visualized as color on the 
membrane (Burnette, 1981, Towbin et al., 1979). The use of nitrocellulose membrane 
was started by Towbin et al. (1979). The name Western blot was given by Burnette 
(1981). There are two apparatus to transfer proteins from gel to nitrocellulose 
membrane, which are buffer-filled tanks (Towbin et al., 1979) and semi-dry 
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(Lauriere, 1993) transfer tool. The apparatus used in this study was semi-dry transfer, 
where the gel and membrane were sandwiched horizontally between 2 stacks of 
buffer-wetted blotting paper within 2 closely spaced solid plate electrode in semi-dry 
transfer unit (Walker and Gravel, 2002).  
 
1.6.6 Statistical test 
1.6.6.1  Wilcoxon paired-sample test 
  Wilcoxon paired-sample is a univariate statistical method introduced by 
Wilcoxon (1945) to test the significant of means differences of paired samples. It is a 
non-parametric test with no assumption about the underlying statistical distribution, 
with at least six paired-samples are needed per class. The null hypothesis is that the 
population median of the paired different of the two samples is zero (Wilcoxon, 
1945). In our case, the paired sample was referred to cancerous and normal tissue 
from the same patient. If the calculated p-value was below 0.05, then the changes of 
protein expression levels between normal and cancerous tissues were statistically 
significant. This test method is available in PDQuest software, which is utilized for 
2D gel images analysis. 
 
1.6.6.2 Principal component analysis (PCA)  
  Followed by the sample processing, proteins extraction and separation, 2D 
gel image and MS analysis, a high dimension of data is created. Therefore, the PCA, 
a multivariate statistical method is utilized to facilitate the data processing (Muir et 
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al., 2007). The theory of PCA was first introduced by Pearson (1901) and then 
further developed by Hotelling (1933). It allows the unsupervised data dimension 
reduction and representation of the original dataset with original variables into a new 
reference system with new variables called Principal Components (PCs) (Hotelling, 
1933, Kim et al., 2009, Marengo et al., 2007, Pearson, 1901, Rodriguez-Pineiro et al., 
2007). The PCs are clustered and measured in hierarchical pattern, where the first 
PCs represent the maximum data variance, the second PCs accounted for the 
maximum residual data variance and so on (Marengo et al., 2007). In our study, PCs 
were referred to the identified protein, where the first PCs represented the most 
differentially expressed protein between normal and cancerous tissue, the second and 
third PCs referred to other differentially expressed proteins in decreasing order, and 
so on. Subsequently, further supervised data reduction can be performed by selecting 
first PCs and preceded to LDA statistical analysis. 
 
1.6.6.3 Linear discriminant analysis (LDA) 
  LDA, which is also known as Bayesian classification method, was first 
introduced by Fisher (1936). It is another multivariate statistical method that 
characterizes the groups, assigning or classifying the cases and measuring the degree 
of success of the classification model (Fisher, 1936, Marengo et al., 2007, 
Rodriguez-Pineiro et al., 2007). In LDA, original variables from PCA are 
transformed into new independent variables called discriminant functions (DF). The 
projection of the data in relation to the DF gives discriminant score. The DF accounts 
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for the maximum amount of separation of the different groups. Finally, LDA 
classifies observations into their respective groups based on their discriminant scores, 
where the groups are mutually exclusive and collectively exhaustive (Sharma and 
Mukherjee, 1996). Wilcoxon paired-sample test, PCA and LDA statistical test results 
are taken into consideration to determine whether the protein is a reliable marker and 
allow the differentiation of normal and cancer state  
 
1.7  Research objectives 
  In view of breast and colorectal cancers are the most common types of 
cancer in Malaysia, we aimed to explore the common differential expressed proteins 
for breast and colorectal cancers using cancerous tissues obtained from human 
patients. These proteins will be valuable for treatment and diagnosis of both cancers. 
Furthermore, comparing the protein expression profile will lead to better 
understanding of the similarity and differences between these two cancers. The 
objectives of this study are: 
a) To map the proteomes of breast and colorectal cancer tissues and their respective 
adjacent normal tissues by using 2D-PAGE. 
b) To compare the differential protein expression on 2D gels. 
i. Breast normal and cancerous tissues according to categories of; 
 All patients 
 Lymph node metastasis 
 Ethnics group of patients 
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ii. Colorectal normal and cancerous tissues according to categories of; 
 All patients 
 Lymph node metastasis 
 Ethnics group of patients 
iii. To identify common and differentially expresses proteins in breast and 
colorectal cancers according to categories of; 
 All patients 
 Lymph node metastasis 
 Ethnics group of patients 
c) To identify the targeted protein using In-gel digestion and LC-MS/MS. 
 
 
 
 
 
 
 
 
 
 
 
 
